ABSTRACT-Characteristics of the association of brotizolam, a thieno-triazolo diazepine derivative, to central benzodiazepine receptors were examined. Brotizolam significantly displaced the [3H]flunitraz epam and [3H]/3-carboline carboxylate ethylester bindings to crude synaptic membrane from the rat brain. This agent had the highest affinity for benzodiazepine receptors in the cerebellum, and it was found to be 2.1 times that in the spinal cord. Furthermore, a low concentration of brotizolam poten tiated the GABA-stimulated 36C1 influx into membrane vesicles. In contrast, the bindings of [3H]8 hydroxy-2-(di-n-propylamino) tetralin to 5-hydroxytryptaminelA receptors and [3H]ketanserin to 5 hydroxytryptamine2 receptors were not affected by brotizolam. The present results suggest that brotizo lam may be a selective and high affinity ligand for the type I central benzodiazepine receptor. The anx iolytic and hypnotic actions of brotizolam seem to be not due to the association with 5-hydroxytrypta mine receptor, but due to the activation of the GABAA receptor complex. Furthermore, the present results suggest that the lower affinity of brotizolam to benzodiazepine receptors in the spinal cord than those in the cerebellum may be related to the low muscle relaxation action of this drug. Brotizolam (8-bromo-6-(o-chlorophenyl)-1-methyl-4H triazolo [3,4-c]thieno[2,3-e]-1,4-diazepine), one of the thieno-triazolo diazepine derivatives, has been clinically used as a hypnotic drug (5). The pharmacological sig nificances of this drug are reported to be no alteration in the duration and frequency of REM sleep in addition to a low potency in muscle relaxation.On the other hand, it has been well-established that the activation of central BZP receptor induces various central actions by affecting GABAergic neurons, since central BZP receptor couples with the GABAA recep tor/Cl channel complex (6). Furthermore, recent phar macological and molecular biological studies have indi cated that both type I BZP receptor, a binding site hav ing high affinity for CL218,872, and type II BZP recep tor, which has lower affinity for CL218,872, are present in the mammalian central nervous system (7,8).In this study, we have examined the characteristics of the actions of brotizolam on the central GABAA receptor/BZP receptor/Cl channel complex using crude synaptic membrane and membrane vesicle prepa rations from the brain and spinal cord.